Subscribe to Newsletter

Daiichi Sankyo invests in Cuorips Inc., an iPS-to-cardiomyocyte based venture company

Cuorips, a startup in Yokohama, has been founded in March 2017 by California-based DEFTA partners, a global investment company. Technology is based on the work of Professor Yoshiki SAWA, a cardiovascular surgeon at Osaka University Graduate School of Medicine, who has developed an allogenic human iPS cell derived cardiomyocyte sheet for the treatment of heart failure and is presently applying for clinical studies. Daiichi Sankyo has obtained the rights to sell iPS-cell derived myocardium sheets from Cuorips worldwide.

Source: Daiichi Sankyo news release, August 7, 2017

Request a quote for deeper information from
contact@asia-tech.eu

© 2017 Window to Japan - Bio 4 Business - Imprint - Terms and Conditions